The Effects of Early Life PUFA and R-TFA on AD: A Systematic Review and Meta-analysis

Sponsor
Sun Yat-sen University (Other)
Overall Status
Completed
CT.gov ID
NCT03344783
Collaborator
(none)
26
1
6.9
3.8

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate whether early life natural exposure to fatty acid affects the AD risk.

Condition or Disease Intervention/Treatment Phase
  • Other: PUFA and R-TFA

Detailed Description

The prevalence of Allergic Diseases (AD) is rising dramatically worldwide especially in more industrialized countries during the past two decades, representing a substantial disease burden of individuals and health service cost. Early life nutritional exposures could modify the gene expression and susceptibility of allergic diseases (AD), yet the effects of early life polyunsaturated fatty acids (PUFA) and ruminant trans fatty acids (R-TFA) on AD remain unclear.Therefore,the investigators performed the meta-analysis and systematic review to evaluate whether early life natural exposure to PUFA and R-TFA affects the AD risk.

Study Design

Study Type:
Observational
Actual Enrollment :
26 participants
Observational Model:
Other
Time Perspective:
Other
Official Title:
The Effects of Early Life Polyunsaturated Fatty Acids and Ruminant Trans Fatty Acids on Allergic Diseases: A Systematic Review and Meta-analysis
Actual Study Start Date :
Mar 15, 2017
Actual Primary Completion Date :
Jun 20, 2017
Actual Study Completion Date :
Oct 10, 2017

Arms and Interventions

Arm Intervention/Treatment
mother-children pairs

Other: PUFA and R-TFA
PUFA and R-TFA exposure were assessed mainly from maternal dietary, blood sample or breast milk. Exposure period was restricted to early life. Dietary PUFA and R-TFA were measured by food-frequency questionnaire (FFQ) or diet history questionnaire (DHQ). The profile of PUFA and R-TFA in the blood sample and breast milk were examined by using gas chromatography

Outcome Measures

Primary Outcome Measures

  1. Eczema were determined by using the validated International Study of Asthma and Allergic in Children (ISAAC) questionnaire or doctors' diagnosis. [From date of inclusion of pregnant women cohort until the date of eczema' diagnosis in children,follow-up time up to 18 years]

    Parental reported questions adapted from the International Study on Asthma and Allergy in Childhood (ISAAC) provided information on eczema.Researchers combined questions into current eczema (no, yes).

  2. Wheeze were determined by using the validated International Study of Asthma and Allergic in Children (ISAAC) questionnaire or doctors' diagnosis. [From date of inclusion of pregnant women cohort until the date of wheeze' diagnosis in children,follow-up time up to 18 years]

    Parental reported questions adapted from the International Study on Asthma and Allergy in Childhood (ISAAC) provided information on wheeze.Researchers combined questions into current wheeze (no, yes).

  3. Asthma were determined by using the validated International Study of Asthma and Allergic in Children (ISAAC) questionnaire or doctors' diagnosis. [From date of inclusion of pregnant women cohort until the date of asthma' diagnosis in children,follow-up time up to 18 years]

    Parental reported questions adapted from the International Study on Asthma and Allergy in Childhood (ISAAC) provided information on asthma.Researchers combined questions into current asthma (no, yes).

  4. Allergic rhinitis were determined by using the validated International Study of Asthma and Allergic in Children (ISAAC) questionnaire or doctors' diagnosis. [From date of inclusion of pregnant women cohort until the date of allergic rhinitis' diagnosis in children,follow-up time up to 18 years]

    Parental reported questions adapted from the International Study on Asthma and Allergy in Childhood (ISAAC) provided information on allergic rhinitis.Researchers combined questions into current allergic rhinitis (no, yes).

  5. Sensitization were determined by IgE test. [From date of inclusion of pregnant women cohort until the date of sensitization' diagnosis in children,follow-up time up to 18 years]

    A child was considered sensitized if the IgE level for at least one of the seven allergens was ≥0.35 kUA/l, and nonsensitized if IgE level for all seven allergens was <0.35 kUA/l.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Studies needed to provide endpoints of AD, and risk estimates [odds risk (OR), relative risk (RR) or hazard ratio (HR)] for PUFA or R-TFA as the exposure. We included English language articles only, while scanned titles /abstracts of non-English language articles to evaluate agreement with the results published in English.
Exclusion Criteria:
  • Studies were excluded if they didn't report the profile of PUFA or R-TFA, or if they targeted participants with medical condition.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Weijia, Wu Guangzhou Guangdong China

Sponsors and Collaborators

  • Sun Yat-sen University

Investigators

  • Study Chair: Li Cai, PhD, Sun Yat-sen University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Li Cai, Principal Investigator, Sun Yat-sen University
ClinicalTrials.gov Identifier:
NCT03344783
Other Study ID Numbers:
  • Weijia,Wu
First Posted:
Nov 17, 2017
Last Update Posted:
Nov 17, 2017
Last Verified:
Nov 1, 2017
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 17, 2017